FDA Grants Accelerated Approval to Tudriqev for Advanced Melanoma

In August 2026, the FDA granted accelerated approval to the engineered oncolytic viral therapy Tudriqev (vusolimogene oderparepvec-wtpg) combined with nivolumab to treat adults with unresectable advanced cutaneous melanoma that progressed with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

When Standard Care Stops Working, Tudriqev Steps In

The FDA has approved Tudriqev, a new oncolytic viral therapy for patients with advanced melanoma that no longer responds to PD-1 blocking therapy. Data from a clinical trial showed that 24% of patients responded to the treatment, with a median response duration of nearly 14 months. The approval was influenced by input from clinical experts and patient advocates highlighting the intense demand for effective options in this refractory population.

Tudriqev, based on a modified herpes simplex virus, targets and destroys cancer cells while stimulating the immune system. It is administered through injection directly into tumors every two weeks, with a combination of nivolumab starting at week three. A trial involving 140 patients with advanced melanoma revealed an objective response rate of 24% among those evaluated.

Karim Mikhail, B. Pharm., M.S., Acting Director of the Center for Biologics Evaluation and Research (CBER), emphasized that for patients with advanced melanoma that has stopped responding to PD-1 blocking therapy, the prognosis is often devastating, and options have been far too limited. Clinicians managing these patients know this urgency firsthand, and this great milestone gives oncologists a meaningful new tool and more patients a fighting chance.
Common side effects included fatigue, fever, and infections, with important safety warnings about the risk of spreading herpes infections and complications from the injection process. This approval provides oncologists with a vital new tool for managing patients in this challenging area.

Impact on the Healthcare Industry

This approval positively impacts the industry by validating a novel therapeutic class, addressing drug resistance limitations, and shifting clinical workflows toward localized, multidisciplinary tumor injection protocols.

This grant impacts the healthcare industry by establishing genetically modified HSV-1 viruses as a core cancer treatment alongside checkpoint inhibitors. It shifts hospital clinical operations for specialized dosing and viral biosafety controls, while rethinking regulatory precedent through flexible approval pathways for single-arm trials addressing intense medical demands.

The impact extends deep into clinical practice and future drug evaluation. Oncology teams must adapt everyday workflows to handle complex intratumoral safety measures. Meanwhile, regulators demonstrate a willingness to clear innovative therapies based on targeted trial designs when patients face critical and unmet medical demands.

This treatment addresses acquired drug resistance by restarting immune activity in tumors that stopped responding to standalone PD-1 therapies. It causes localized tumor cell death, releasing signals that wake up a dormant immune system. It also offers durable responses in hard-to-treat settings. Patients achieve a meaningful 24% objective response rate with a long median response duration of 14.1 months.

Impact on the Oncology Industry

The global oncology market size was calculated at USD 250.88 billion in 2025 and is predicted to increase from USD 279.73 billion in 2026 to approximately USD 732.45 billion by 2035, expanding at a CAGR of 11.31% from 2026 to 2035.

According to Precedence Research, this grant contributes to the oncology industry by offering a vital new option for patients who stopped responding to standard anti-PD-1 immunotherapy.

This breakthrough validates oncolytic platforms by demonstrating that genetically modified herpes simplex viruses can transform cold tumors into hot, immune-responsive targets. It also redefines salvage therapy for post-PD-1 failure by establishing a benchmark that shifts treatment away from toxic chemotherapy. Furthermore, the approval sets regulatory standards by overcoming prior rejections through strong advisory committee support, establishing a pathway for single-arm trial data packages, offering new options for patients who have not responded to standard checkpoint inhibitor therapies, and paving the way for future approvals of viral immunotherapies.

This also addresses industry challenges by targeting drug resistance, lowering systemic toxicity, and simplifying dosing. It re-awakens immune responses against checkpoint inhibitor resistance through local cell lysis and tumor antigen release. Direct tumor injection also limits side effects compared with traditional cytotoxic drugs. It also streamlines clinical administration for oncology teams with a clear, measurement-based dosing formula of 1 mL per centimeter of tumor size. This localized approach optimizes patient safety by making treatment delivery much more practical and predictable in a hospital setting.